
Bo Peng
Examiner (ID: 19836)
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, CQIC, 4171, 4111 |
| Total Applications | 343 |
| Issued Applications | 135 |
| Pending Applications | 38 |
| Abandoned Applications | 170 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 363305
[patent_doc_number] => 07482115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-01-27
[patent_title] => 'Immobilisation and stabilisation of virus'
[patent_app_type] => utility
[patent_app_number] => 10/512635
[patent_app_country] => US
[patent_app_date] => 2003-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 5692
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/482/07482115.pdf
[firstpage_image] =>[orig_patent_app_number] => 10512635
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/512635 | Immobilisation and stabilisation of virus | Apr 27, 2003 | Issued |
Array
(
[id] => 6821574
[patent_doc_number] => 20030219735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-11-27
[patent_title] => 'Metabolically activated recombinant viral vectors and methods for their preparation and use'
[patent_app_type] => new
[patent_app_number] => 10/423507
[patent_app_country] => US
[patent_app_date] => 2003-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 21950
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0219/20030219735.pdf
[firstpage_image] =>[orig_patent_app_number] => 10423507
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/423507 | Metabolically activated recombinant viral vectors and methods for their preparation and use | Apr 24, 2003 | Issued |
Array
(
[id] => 6966414
[patent_doc_number] => 20050233311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-10-20
[patent_title] => 'Family of picornaviruses'
[patent_app_type] => utility
[patent_app_number] => 10/512392
[patent_app_country] => US
[patent_app_date] => 2003-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 1953
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0233/20050233311.pdf
[firstpage_image] =>[orig_patent_app_number] => 10512392
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/512392 | Family of picornaviruses | Apr 22, 2003 | Abandoned |
Array
(
[id] => 4521093
[patent_doc_number] => 07951379
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-05-31
[patent_title] => 'Hollow nanoparticle of NBsAg large protein for drug delivery'
[patent_app_type] => utility
[patent_app_number] => 10/509249
[patent_app_country] => US
[patent_app_date] => 2003-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 28
[patent_no_of_words] => 13829
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/951/07951379.pdf
[firstpage_image] =>[orig_patent_app_number] => 10509249
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/509249 | Hollow nanoparticle of NBsAg large protein for drug delivery | Mar 25, 2003 | Issued |
Array
(
[id] => 5742817
[patent_doc_number] => 20060088542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-04-27
[patent_title] => 'Imidazoquinoline adjuvants for vaccines'
[patent_app_type] => utility
[patent_app_number] => 10/508143
[patent_app_country] => US
[patent_app_date] => 2003-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 25086
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0088/20060088542.pdf
[firstpage_image] =>[orig_patent_app_number] => 10508143
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/508143 | Imidazoquinoline adjuvants for vaccines | Mar 18, 2003 | Abandoned |
Array
(
[id] => 7466485
[patent_doc_number] => 20040101957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-05-27
[patent_title] => 'Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications'
[patent_app_type] => new
[patent_app_number] => 10/380641
[patent_app_country] => US
[patent_app_date] => 2003-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 145
[patent_figures_cnt] => 145
[patent_no_of_words] => 41205
[patent_no_of_claims] => 89
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0101/20040101957.pdf
[firstpage_image] =>[orig_patent_app_number] => 10380641
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/380641 | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications | Mar 13, 2003 | Abandoned |
Array
(
[id] => 7469577
[patent_doc_number] => 20040054139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-03-18
[patent_title] => 'Modification of hepatitis b core antigen'
[patent_app_type] => new
[patent_app_number] => 10/312045
[patent_app_country] => US
[patent_app_date] => 2003-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 7886
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0054/20040054139.pdf
[firstpage_image] =>[orig_patent_app_number] => 10312045
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/312045 | Modification of hepatitis b core antigen | Mar 10, 2003 | Abandoned |
Array
(
[id] => 7136080
[patent_doc_number] => 20050181064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-08-18
[patent_title] => 'Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith'
[patent_app_type] => utility
[patent_app_number] => 10/509247
[patent_app_country] => US
[patent_app_date] => 2003-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 9472
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0181/20050181064.pdf
[firstpage_image] =>[orig_patent_app_number] => 10509247
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/509247 | Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith | Mar 4, 2003 | Abandoned |
Array
(
[id] => 5873038
[patent_doc_number] => 20060165726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-07-27
[patent_title] => 'Remedies with the use of hollow protein nanoparticles presenting growth factor or the like'
[patent_app_type] => utility
[patent_app_number] => 10/509248
[patent_app_country] => US
[patent_app_date] => 2003-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 5458
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0165/20060165726.pdf
[firstpage_image] =>[orig_patent_app_number] => 10509248
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/509248 | Remedies with the use of hollow protein nanoparticles presenting growth factor or the like | Mar 4, 2003 | Abandoned |
Array
(
[id] => 6730241
[patent_doc_number] => 20030186431
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-10-02
[patent_title] => 'Rabbit hemorrhagic disease vaccine and antigens'
[patent_app_type] => new
[patent_app_number] => 10/363503
[patent_app_country] => US
[patent_app_date] => 2003-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 6478
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0186/20030186431.pdf
[firstpage_image] =>[orig_patent_app_number] => 10363503
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/363503 | Rabbit hemorrhagic disease vaccine and antigens | Mar 2, 2003 | Abandoned |
Array
(
[id] => 5613886
[patent_doc_number] => 20060115814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-06-01
[patent_title] => 'Methods and compositions, relating to hiv gp41 antigens and other hiv envelope antigens'
[patent_app_type] => utility
[patent_app_number] => 10/506095
[patent_app_country] => US
[patent_app_date] => 2003-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 25693
[patent_no_of_claims] => 62
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0115/20060115814.pdf
[firstpage_image] =>[orig_patent_app_number] => 10506095
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/506095 | Methods and compositions, relating to hiv gp41 antigens and other hiv envelope antigens | Feb 25, 2003 | Abandoned |
Array
(
[id] => 6821738
[patent_doc_number] => 20030219899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-11-27
[patent_title] => 'Mosaic adenoviral vectors'
[patent_app_type] => new
[patent_app_number] => 10/372615
[patent_app_country] => US
[patent_app_date] => 2003-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 18247
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0219/20030219899.pdf
[firstpage_image] =>[orig_patent_app_number] => 10372615
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/372615 | Mosaic adenoviral vectors | Feb 20, 2003 | Abandoned |
Array
(
[id] => 6678180
[patent_doc_number] => 20030228320
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-12-11
[patent_title] => 'Retroviral immunotherapy'
[patent_app_type] => new
[patent_app_number] => 10/369256
[patent_app_country] => US
[patent_app_date] => 2003-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 13003
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0228/20030228320.pdf
[firstpage_image] =>[orig_patent_app_number] => 10369256
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/369256 | Retroviral immunotherapy | Feb 17, 2003 | Abandoned |
Array
(
[id] => 6829266
[patent_doc_number] => 20030180324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-09-25
[patent_title] => 'Lentivirus from the group of immunodeficiency viruses of drill monkeys (Mandrillus leucophaeus) and their use'
[patent_app_type] => new
[patent_app_number] => 10/364360
[patent_app_country] => US
[patent_app_date] => 2003-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 7897
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0180/20030180324.pdf
[firstpage_image] =>[orig_patent_app_number] => 10364360
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/364360 | Lentivirus from the group of immunodeficiency viruses of drill monkeys (Mandrillus leucophaeus) and their use | Feb 11, 2003 | Abandoned |
Array
(
[id] => 6664542
[patent_doc_number] => 20030203868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-10-30
[patent_title] => 'Inhibition of pathogen replication by RNA interference'
[patent_app_type] => new
[patent_app_number] => 10/361161
[patent_app_country] => US
[patent_app_date] => 2003-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 17559
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0203/20030203868.pdf
[firstpage_image] =>[orig_patent_app_number] => 10361161
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/361161 | Inhibition of pathogen replication by RNA interference | Feb 5, 2003 | Abandoned |
Array
(
[id] => 7143645
[patent_doc_number] => 20050118567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-06-02
[patent_title] => 'Method for determining sensitivity to a bacteriophage'
[patent_app_type] => utility
[patent_app_number] => 10/498428
[patent_app_country] => US
[patent_app_date] => 2003-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 12330
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0118/20050118567.pdf
[firstpage_image] =>[orig_patent_app_number] => 10498428
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/498428 | Method for determining sensitivity to a bacteriophage | Jan 22, 2003 | Abandoned |
Array
(
[id] => 7152621
[patent_doc_number] => 20050025780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-02-03
[patent_title] => 'Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations'
[patent_app_type] => utility
[patent_app_number] => 10/501570
[patent_app_country] => US
[patent_app_date] => 2003-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 10572
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0025/20050025780.pdf
[firstpage_image] =>[orig_patent_app_number] => 10501570
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/501570 | Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations | Jan 21, 2003 | Abandoned |
Array
(
[id] => 6805351
[patent_doc_number] => 20030232745
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-12-18
[patent_title] => 'Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection'
[patent_app_type] => new
[patent_app_number] => 10/328997
[patent_app_country] => US
[patent_app_date] => 2002-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 37958
[patent_no_of_claims] => 206
[patent_no_of_ind_claims] => 59
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0232/20030232745.pdf
[firstpage_image] =>[orig_patent_app_number] => 10328997
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/328997 | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection | Dec 23, 2002 | Abandoned |
Array
(
[id] => 556179
[patent_doc_number] => 07157259
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2007-01-02
[patent_title] => 'Murine lecithin-cholesterol acyltransferase protein'
[patent_app_type] => utility
[patent_app_number] => 10/323051
[patent_app_country] => US
[patent_app_date] => 2002-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 18
[patent_no_of_words] => 36062
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/157/07157259.pdf
[firstpage_image] =>[orig_patent_app_number] => 10323051
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/323051 | Murine lecithin-cholesterol acyltransferase protein | Dec 17, 2002 | Issued |
Array
(
[id] => 7437940
[patent_doc_number] => 20040002581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-01-01
[patent_title] => 'Peptides and use thereof in therapeutic agents against HIV infection'
[patent_app_type] => new
[patent_app_number] => 10/305133
[patent_app_country] => US
[patent_app_date] => 2002-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5533
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0002/20040002581.pdf
[firstpage_image] =>[orig_patent_app_number] => 10305133
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/305133 | Peptides and use thereof in therapeutic agents against HIV infection | Nov 26, 2002 | Abandoned |